I have plenty of BLT. But I am tempted to buy more on this kind of announcement. There is a clear confidence by management that TT-034 will work. Otherwise why would you build optionality of manufacture scalability which must cost more? Looking good IMO. Now that biotechs are hot again I wouldn't be surprised if this goes for a run now.
